We are live on ! Find out more
FOMX

Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX

Delisted

FOMX was delisted on the 6th of March, 2020.

84 hedge funds and large institutions have $164M invested in Foamix Pharmaceuticals Ltd. Ordinary Shares in 2015 Q2 according to their latest regulatory filings, with 58 funds opening new positions, 18 increasing their positions, 5 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,350% more first-time investments, than exits

New positions opened: 58 | Existing positions closed: 4

260% more repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 5

171% more funds holding

Funds holding: 3184 (+53)

139% more capital invested

Capital invested by funds: $68.7M → $164M (+$95.3M)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

Holders
84
Holders Change
+53
Holders Change %
+170.97%
% of All Funds
2.26%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
58
Increased
18
Reduced
5
Closed
4
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
BBA
1
Baker Bros. Advisors
New York
$21M +$2.49M +225,000 +12%
Franklin Resources
2
Franklin Resources
California
$16M +$17.3M +1,562,800 New
MMH
3
Menora Mivtachim Holdings
Israel
$11.6M +$8.03M +726,269 +178%
DA
4
DSC Advisors
Illinois
$10.1M +$1.25M +113,081 +13%
DM
5
Deerfield Management
New York
$9.73M +$2.98M +269,307 +40%
VAM
6
Visium Asset Management
New York
$7.93M +$8.55M +774,000 New
SAM
7
Senzar Asset Management
New York
$7.25M +$1.54M +138,900 +24%
Bank of New York Mellon
8
Bank of New York Mellon
New York
$6.72M +$7.25M +655,879 New
BFA
9
BlackRock Fund Advisors
California
$6.08M +$6.34M +573,615 +2,978%
Alyeska Investment Group
10
Alyeska Investment Group
Illinois
$4.83M +$2.98M +270,028 +134%
PHS
11
PFM Health Sciences
California
$4.58M +$4.94M +446,909 New
TCM
12
Tekla Capital Management
Massachusetts
$4.24M +$4.57M +413,800 New
JGC
13
J. Goldman & Co
New York
$4.15M +$4.48M +405,000 New
SFM
14
Sphera Funds Management
Israel
$3.9M +$1.99M +180,000 +90%
DCM
15
Driehaus Capital Management
Illinois
$3.87M +$629K +56,874 +18%
Acadian Asset Management
16
Acadian Asset Management
Massachusetts
$3.7M +$3.48M +315,093 +690%
UBS AM
17
UBS AM
Illinois
$2.93M +$3.16M +286,299 New
EI
18
EAM Investors
California
$2.68M +$2.89M +261,161 New
GTC
19
Ghost Tree Capital
New York
$2.56M +$2.76M +250,000 New
PCM
20
Pentwater Capital Management
Florida
$2.04M -$5.31M -480,868 -71%
Baillie Gifford & Co
21
Baillie Gifford & Co
United Kingdom
$1.94M +$2.09M +189,400 New
State Street
22
State Street
Massachusetts
$1.84M +$1.98M +179,139 New
SM
23
Sabby Management
Florida
$1.8M +$1.78M +160,700 +1,050%
FCM
24
Farallon Capital Management
California
$1.74M +$1.88M +170,000 New
BIT
25
BlackRock Institutional Trust
California
$1.7M +$1.84M +166,031 New

FOMX Hedge Fund Activity: Q2 2015 in Review

84 of the 3,711 institutional investors tracked by Wall St. Rank reported a position in Foamix Pharmaceuticals Ltd. Ordinary Shares (FOMX) for Q2 2015, worth a combined $164M — up 139% from $68.7M a quarter earlier.

Buyers outnumbered sellers: 58 funds opened new FOMX positions and 4 closed out — a net gain of 54 holders — while 18 added to existing stakes and 5 trimmed.

The largest buyer was Franklin Resources, opening a new position worth an estimated $17.3M. The largest seller was Jennison Associates, exiting entirely with an estimated $10.1M sold.

  • 84 institutional investors held Foamix Pharmaceuticals Ltd. Ordinary Shares (FOMX) as of Q2 2015, up from 31 in Q1 2015.
  • Funds reported $164M of Foamix Pharmaceuticals Ltd. Ordinary Shares stock for Q2 2015, up 139% quarter-over-quarter.
  • 58 funds opened new Foamix Pharmaceuticals Ltd. Ordinary Shares positions in Q2 2015 and 4 closed out, a net change of +54 holders.
  • The largest Foamix Pharmaceuticals Ltd. Ordinary Shares buyer in Q2 2015 was Franklin Resources, an estimated $17.3M added.
  • The largest Foamix Pharmaceuticals Ltd. Ordinary Shares seller in Q2 2015 was Jennison Associates, an estimated $10.1M sold.

Based on aggregated 13F filings for Q2 2015.